Carcinoid heart disease: The role of urinary 5‐hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor‐β and fibroblast growth factor
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Serotonin excretion plays a role in the development of carcinoid heart disease (CHD), but the exact pathogenesis is not known. In the current study, the authors evaluated 24‐hour urinary 5‐hydroxyindoleacetic acid (5‐HIAA) excretion, as well as plasma levels of transforming growth factor‐β (TGF‐β), fibroblast growth factor (FGF), and atrial natriuretic peptide (ANP) in patients with and without CHD determined by ultrasound examination. METHODS: Urine and plasma samples were obtained for 37 patients and cardiac ultrasound was performed during follow‐up in 1999 and 2000. Median 5‐HIAA excretion was calculated for the period between diagnosis and ultrasound examination. CHD was defined as the thickening of the tricuspid valve with additional III–IV/IV tricuspid valve regurgitation. RESULTS: CHD was found in 9 of 37 patients (24%). No significant differences were found for age, gender, presence, and duration of liver metastases. All CHD patients had symptoms of the carcinoid syndrome compared with 71% of the non‐CHD patients (P = 0.159). Median 5‐HIAA excretion was significantly higher in the CHD group compared with the non‐CHD group: 576 μmol/24 hours versus 233 μmol/24 hours (P = 0.02). No difference in TGF‐β and FGF plasma levels was observed between both groups (P = 0.139 and P = 0.985, respectively), nor was there a correlation with morphology of the tricuspid valve or degree of dilatation of the right atrium/ventricle. However, the CHD group had higher median ANP levels than the non‐CHD group: 48 ng/L and 25 ng/L, respectively (P = 0.026). CONCLUSIONS: High levels of 5‐HIAA excretion and plasma ANP were found to be associated with CHD. No significant relation with TGF‐β or FGF was been found. Cancer 2003;97:1609–15. © 2003 American Cancer Society. DOI 10.1002/cncr.11226
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Cited by
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum
Niederle, B., Pape, U.-F., Costa, F., Gross, D., Kelestimur, F., Knigge, U., Öberg, K., Pavel, M., Perren, A., Toumpanakis, C., et al. (2016) · Neuroendocrinology · doi:10.1159/000443170 · Cited by 474
Pape, U.-F., Perren, A., Niederle, B., Gross, D., Gress, T., Costa, F., Arnold, R., Denecke, T., Plöckinger, U., Salazar, R., et al. (2012) · Neuroendocrinology · doi:10.1159/000335629 · Cited by 465
Jann, H., Roll, S., Couvelard, A., Hentic, O., Pavel, M., Müller‐Nordhorn, J., Koch, M., Röcken, C., Rindi, G., Ruszniewski, P., et al. (2011) · Cancer · doi:10.1002/cncr.25855 · Cited by 289
Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors
Davar, J., Connolly, H. M., Caplin, M. E., Pavel, M., Zacks, J., Bhattacharyya, S., Cuthbertson, D. J., Dobson, R., Grozinsky-Glasberg, S., Steeds, R. P., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.030 · Cited by 261
Metadata
- Authors
- Zuetenhorst, J. M., Bonfrer, J. M. G. M., Korse, C. M., Bakker, R., van Tinteren, H., & Taal, B. G.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-03-18
- Volume
- 97
- Issue
- 7
- Pages
- 1609-1615
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2031213425
- Cited by
- 126
- References
- 1
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Carcinoid heart disease: The role of urinary 5‐hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor‐β and fibroblast growth factor. https://app.cochat.ai/papers/10.1002/cncr.11226
- The paper
- Zuetenhorst, J. M., Bonfrer, J. M. G. M., Korse, C. M., Bakker, R., van Tinteren, H., & Taal, B. G. (2003). Carcinoid heart disease: The role of urinary 5‐hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor‐β and fibroblast growth factor. Cancer. https://doi.org/10.1002/cncr.11226
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.